Therapies and Therapeutic Approaches in Congenital Disorders of Glycosylation

Overview

Journal Glycoconj J

Publisher Springer

Specialties Biochemistry
Endocrinology

Date 2012 Sep 18

PMID 22983739

Citations 7

Authors

Christian Thiel

Christian Korner

Affiliations

Soon will be listed here.

Abstract

Inborn errors in glycoconjugate biosynthesis termed 'Congenital Disorders of Glycosylation' (CDG) comprise a rapidly expanding group of metabolic diseases in man. Up till now more than 60 different inherited disorders in N- and O-glycosylation pathways have been identified. They affect the biosynthesis of glycan moieties linked to proteins as well as lipids. Due to failures in protein glycosylation, CDG patients suffer from multi systemic disorders, which mostly present with severe psychomotor and mental retardations, muscular impairment, ataxia, failure to thrive and developmental delay. Although improved biochemical and genetic investigations led to identification of a variety of new molecular defects in glycoconjugate biosynthesis, effective therapies for most types of the CDG are so far not available. Therefore, intensive investigations on treatment options for this group of diseases have been carried out in recent years.

Citing Articles

L-fucose, a sugary regulator of antitumor immunity and immunotherapies.

Adhikari E, Liu Q, Burton C, Mockabee-Macias A, Lester D, Lau E Mol Carcinog. 2022; 61(5):439-453.

PMID: 35107186 PMC: 9097813. DOI: 10.1002/mc.23394.

Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG).

Taday R, Gruneberg M, DuChesne I, Reunert J, Marquardt T Orphanet J Rare Dis. 2020; 15(1):258.

PMID: 32962735 PMC: 7510076. DOI: 10.1186/s13023-020-01528-z.

CDG Therapies: From Bench to Bedside.

Brasil S, Pascoal C, Francisco R, Marques-da-Silva D, Andreotti G, Videira P Int J Mol Sci. 2018; 19(5).

PMID: 29702557 PMC: 5983582. DOI: 10.3390/ijms19051304.

Public and patient involvement in needs assessment and social innovation: a people-centred approach to care and research for congenital disorders of glycosylation.

De Freitas C, Dos Reis V, Silva S, Videira P, Morava E, Jaeken J BMC Health Serv Res. 2017; 17(1):682.

PMID: 28950866 PMC: 5615629. DOI: 10.1186/s12913-017-2625-1.

O-Glycosylation of a Secretory Granule Membrane Enzyme Is Essential for Its Endocytic Trafficking.

Vishwanatha K, Back N, Lam T, Mains R, Eipper B J Biol Chem. 2016; 291(18):9835-50.

PMID: 26961877 PMC: 4850319. DOI: 10.1074/jbc.M115.711838.

References

Song Y, Willer J, Scherer P, Panzer J, Kugath A, Skordalakes E . Neural and synaptic defects in slytherin, a zebrafish model for human congenital disorders of glycosylation. PLoS One. 2010; 5(10):e13743. PMC: 2966427. DOI: 10.1371/journal.pone.0013743. View

Dube D, Bertozzi C . Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005; 4(6):477-88. DOI: 10.1038/nrd1751. View

Mayatepek E, Schroder M, Kohlmuller D, Bieger W, Nutzenadel W . Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr. 1997; 86(10):1138-40. DOI: 10.1111/j.1651-2227.1997.tb14825.x. View

Sharma V, Ichikawa M, He P, Scott D, Bravo Y, Dahl R . Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts. J Biol Chem. 2011; 286(45):39431-8. PMC: 3234766. DOI: 10.1074/jbc.M111.285502. View

Panneerselvam K, Freeze H . Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J Clin Invest. 1996; 97(6):1478-87. PMC: 507208. DOI: 10.1172/JCI118570. View

Luhn K, Marquardt T, Harms E, Vestweber D . Discontinuation of fucose therapy in LADII causes rapid loss of selectin ligands and rise of leukocyte counts. Blood. 2001; 97(1):330-2. DOI: 10.1182/blood.v97.1.330. View

Barresi R, Michele D, Kanagawa M, Harper H, Dovico S, Satz J . LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med. 2004; 10(7):696-703. DOI: 10.1038/nm1059. View

Kjaergaard S, Kristiansson B, Stibler H, Freeze H, Schwartz M, Martinsson T . Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr. 1998; 87(8):884-8. DOI: 10.1080/080352598750013680. View

Schachter H, Freeze H . Glycosylation diseases: quo vadis?. Biochim Biophys Acta. 2008; 1792(9):925-30. PMC: 3927646. DOI: 10.1016/j.bbadis.2008.11.002. View

10.

Luhn K, Wild M, Eckhardt M, Gerardy-Schahn R, Vestweber D . The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet. 2001; 28(1):69-72. DOI: 10.1038/ng0501-69. View

11.

Mention K, Lacaille F, Valayannopoulos V, Romano S, Kuster A, Cretz M . Development of liver disease despite mannose treatment in two patients with CDG-Ib. Mol Genet Metab. 2007; 93(1):40-3. DOI: 10.1016/j.ymgme.2007.08.126. View

12.

Rutschow S, Thiem J, Kranz C, Marquardt T . Membrane-permeant derivatives of mannose-1-phosphate. Bioorg Med Chem. 2002; 10(12):4043-9. DOI: 10.1016/s0968-0896(02)00269-9. View

13.

Theodore M, Morava E . Congenital disorders of glycosylation: sweet news. Curr Opin Pediatr. 2011; 23(6):581-7. DOI: 10.1097/MOP.0b013e32834cd693. View

14.

Liem Y, Bode L, Freeze H, Leebeek F, Zandbergen A, Wilson J . Using heparin therapy to reverse protein-losing enteropathy in a patient with CDG-Ib. Nat Clin Pract Gastroenterol Hepatol. 2008; 5(4):220-4. DOI: 10.1038/ncpgasthep1061. View

15.

Thiel C, Korner C . Mouse models for congenital disorders of glycosylation. J Inherit Metab Dis. 2011; 34(4):879-89. DOI: 10.1007/s10545-011-9295-7. View

16.

Moskal J, Kroes R, Dawson G . The glycobiology of brain tumors: disease relevance and therapeutic potential. Expert Rev Neurother. 2009; 9(10):1529-45. DOI: 10.1586/ern.09.105. View

17.

DeRossi C, Bode L, A Eklund E, Zhang F, Davis J, Westphal V . Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality. J Biol Chem. 2005; 281(9):5916-27. DOI: 10.1074/jbc.M511982200. View

18.

A Eklund E, Merbouh N, Ichikawa M, Nishikawa A, Clima J, Dorman J . Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblasts. Glycobiology. 2005; 15(11):1084-93. DOI: 10.1093/glycob/cwj006. View

19.

Bertini E, DAmico A, Gualandi F, Petrini S . Congenital muscular dystrophies: a brief review. Semin Pediatr Neurol. 2011; 18(4):277-88. PMC: 3332154. DOI: 10.1016/j.spen.2011.10.010. View

20.

Korner C, Lehle L, von Figura K . Carbohydrate-deficient glycoprotein syndrome type 1: correction of the glycosylation defect by deprivation of glucose or supplementation of mannose. Glycoconj J. 1999; 15(5):499-505. DOI: 10.1023/a:1006939104442. View